JP Morgan Chase
DAWN

JP Morgan Chase’s Day One Biopharmaceuticals DAWN Stock Holding History

JP Morgan Chase’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.07M Buy
+190,000
New +$2.68M ﹤0.01% 3509

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's DAWN Position: Q1 2026 in Review

JP Morgan Chase increased its Day One Biopharmaceuticals (DAWN) stake by 7,101% in Q1 2026, buying an estimated $43.6M and bringing the position to 3,134,753 shares worth $67.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

JP Morgan Chase first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • JP Morgan Chase held 3,134,753 shares of Day One Biopharmaceuticals worth $67.1M as of Q1 2026.
  • JP Morgan Chase bought 3,091,223 Day One Biopharmaceuticals shares in Q1 2026, an estimated $43.6M.
  • Day One Biopharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1205 holding.
  • JP Morgan Chase first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.